-
Mashup Score: 1
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, gives an overview of bispecific antibodies emerging in multiple myeloma, drawing focus…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology. #SOHO22 #ALL #leusm | @MDAndersonNews https://t.co/3c4B3qQW6z
-
-
Mashup Score: 0
In this video, Saad Kenderian, MB, CHB, Mayo Clinic, Rochester, MN, discusses the challenges associated with using CAR-T cell therapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Saad Kenderian (@kenderian_ss) of @MayoClinic discusses the current challenges and opportunities regarding CAR-T cell therapy and the tumor microenvironment at #SOHO22: 🎥: https://t.co/xyr76oZmuS #HemOnc #ImmunoOnc #CARTcell
-
-
Mashup Score: 0Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more - 1 year(s) ago
The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton’s tyrosine…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 Join us for another weekly podcast! In this week's podcast, you will hear the latest updates in CLL with experts Nitin Jain & Catherine Coombs from #SOHO22! 🎧: https://t.co/jEclu71gx5 #CLLsm #LeuSM #HemOnc #ImmunoOnc
-
-
Mashup Score: 0
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, shares some insights into challenges in developing bispecific…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#SOHO22 | Michael Dickinson (@mike_dickinson1) discusses the challenges in developing bispecific antibodies for NHL. Watch here: 🎥: https://t.co/uiZQOmbyL7 #LymSM #HemOnc #ImmunoOnc #NHL @SocietyofHemOnc
-
-
Mashup Score: 0An insight into the biology of CHIP and CCUS and their role in hematological malignancies - 1 year(s) ago
Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares some insights into the biology of clonal hematopoiesis of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amir Fathi (@MassGeneralNews) shares some insights into the biology of CHIP and CCUS and their role in the development of hematological malignancies: 👉https://t.co/11zRi3jyOc👈 @SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #MDSsm
-
-
Mashup Score: 0LP-284 Shows Preclinical Activity in ATM-Mutated MCL - 1 year(s) ago
An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The investigational agent LP-284 demonstrated activity in multiple mantle cell lymphoma cell lines, according to preclinical research presented in a poster at #SOHO22. #MCL #lymsm https://t.co/GychFkkIqi
-
-
Mashup Score: 0Novel treatment approaches in BPDCN: the promise of CD123-targeting allogeneic CAR-T cells - 1 year(s) ago
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, discusses novel treatment approaches for blastic plasmacytoid dendritic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about novel treatment approaches in BPDCN, including the promise of CD123-targeting allogeneic CAR-T cells, in our exclusive interview with Marina Konopleva (@EinsteinMed): 👉https://t.co/EMAuFu61MH👈 #HemOnc #RareDiseases #ImmunoOnc #CARTcell #SOHO22
-
-
Mashup Score: 0CLL Sessions: Key highlights from SOHO 2022 | VJHemOnc - 1 year(s) ago
Welcome to The CLL Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session features a roundtable discussion from the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), with leading experts Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Catherine Coombs, MD, University of North Carolina, Chapel Hill,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Tune in to our latest session with experts @NitinJainMD & @calliecoombsmd (@UCIrvineHealth) who discuss key highlights in CLL at #SOHO22. Topics covered: ➡️ The changing role of chemotherapy ➡️ Novel BTKis ➡️ Treating Richter's syndrome & more! 👉https://t.co/cd0x4AyQxA👈 https://t.co/NAaXSGGjx4
-
-
Mashup Score: 1Standard of care treatment approaches in MCL and the role of chemotherapy-free regimens - 1 year(s) ago
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses standard of care treatment approaches in mantle cell lymphoma (MCL)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Umberto Vitolo (@fpoirccs) shares some insights into standard of care treatment approaches in mantle cell lymphoma, the role of chemotherapy-free regimens & the promise of CAR-T therapy: 👉https://t.co/VhQ7GesSh4👈 #SOHO22 #LymSM #HemOnc #ImmunoOnc #CARTcell
-
Peter Voorhees of @LevineCancer gives an overview of bispecific antibodies being explored in multiple myeloma, including teclistamab, talquetamab, and cevostamab. Watch now: 🎥: https://t.co/x05cJfPFBE @SocietyofHemOnc #SOHO22 #HemOnc #MMsm #ImmunoOnc